Atea Pharmaceuticals, Inc.
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Atea Pharmaceuticals, Inc.
- Company name
- Atea Pharmaceuticals, Inc.
- Organisation type
- Industry
- Registered legal name
- Atea Pharmaceuticals, Inc.
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- SEC filer number (CIK)
- 0001593899
Related records
Trials (36)
- A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
- A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study
- Bronchopulmonary PK of AT-527 (R07496998)
- C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
- C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
- Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir
- Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)
- Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)
- Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir
- Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)
- Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir
- Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527
- Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)
- Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)
- Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir
- Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting
- Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection